Laboratory of Molecular Biology, Fundación Instituto Valenciano de Oncología, Valencia, Spain.
Int J Cancer. 2011 Mar 1;128(5):1139-50. doi: 10.1002/ijc.25424.
More than 90% of all Ewing's Sarcoma Family of Tumors (ESFT) exhibit specific chromosomal rearrangements between the EWS gene on chromosome 22 and various members of the ETS gene family of transcription factors. The gene fusion type and other secondary genetic alterations, mainly involving cell cycle regulators, have been shown to be of prognostic relevance in ESFT. However, no conclusive results have been reported. We analyzed the clinicopathological significance of relevant cell cycle regulators in genetically confirmed ESFT. A total of 324 cases were analyzed for the immunohistochemical expression of p53, p21(Waf1/Cip1) , p27(Kip1) and Ki67 and the chromosomal alterations of the p53 and 9p21 locus by fluorescent in situ hybridization. We observed that expression of p53 (p = 0.025), p21(Waf1/Cip1) (p = 0.015) and p27(Kip1) (p = 0.013) was higher in disseminated than in localized disease. Furthermore, a cohort of 217 patients with localized disease was considered for studying the prognosis involvement of these factors on patient follow-up. The median follow-up was 39 months (range: 0.17-452) with an overall survival (OS) of 55%. Ki67 was expressed in 34% of cases and constituted an independent prognostic factor for progression free survival and OS independently of the type of treatment [hazard ratio of 2.0 (95% CI: 1.3-3.1; p = 0.003) and 1.9 (95% IC: 1.3-2.9; p = 0.007) for progression free survival and OS, respectively, being especially relevant in the group of patients which incorporated radiotherapy in their regimen schedules. In conclusion, this study demonstrates that Ki67 expression constitutes a valuable indicator of poor prognosis in localized ESFT.
超过 90%的尤文氏肉瘤家族肿瘤(ESFT)表现出 EWS 基因与 ETS 基因家族转录因子的特定染色体重排。基因融合类型和其他次要遗传改变,主要涉及细胞周期调节剂,已被证明与 ESFT 的预后相关。然而,目前还没有得出明确的结论。我们分析了遗传确认的 ESFT 中相关细胞周期调节剂的临床病理意义。共分析了 324 例病例的 p53、p21(Waf1/Cip1)、p27(Kip1)和 Ki67 的免疫组织化学表达以及通过荧光原位杂交的 p53 和 9p21 基因座的染色体改变。我们观察到,p53(p=0.025)、p21(Waf1/Cip1)(p=0.015)和 p27(Kip1)(p=0.013)的表达在播散性疾病中高于局限性疾病。此外,我们考虑了一组 217 例局限性疾病患者,以研究这些因素对患者随访预后的影响。中位随访时间为 39 个月(范围:0.17-452),总体生存率(OS)为 55%。Ki67 在 34%的病例中表达,并且是无进展生存率和 OS 的独立预后因素,独立于治疗类型[危险比为 2.0(95%可信区间:1.3-3.1;p=0.003)和 1.9(95%可信区间:1.3-2.9;p=0.007),分别对于无进展生存率和 OS,在纳入放疗方案的患者组中具有特别重要的意义。总之,这项研究表明,Ki67 的表达是局限性 ESFT 不良预后的一个有价值的指标。